Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bispecific Killer Cell Engager (BiKE)
- Target
- BiKE
- Molecular classification
- Engineered antibody fragment, Immunotherapeutic, Bispecific antibody
01
Overview
A bispecific killer cell engager (BiKE) is an engineered antibody-based immunotherapeutic designed to simultaneously bind two different target proteins: one on natural killer (NK) cells (e.g., CD16, NKG2D, NKp46) and another on tumor or diseased cells. This dual binding brings NK cells into close proximity with their targets, facilitating immune-mediated destruction of the target cell. BiKEs are primarily being developed for cancer immunotherapy, including hematological malignancies and solid tumors.
- Other names
- BiKEsBispecific NK cell engagerCD16 bispecific killer cell engager
02
Mechanism of action
Binds both NK cells and target cells, activating NK cells and inducing target cell lysis.
03
Biological functions
Immune cell redirectionTargeted cell lysisNK cell activationCytotoxicity induction
04
Disease associations
CancerHematological malignanciesSolid tumors
05
Safety considerations
Off-target effectsCytokine release syndrome
06
Interacting drugs
CD16xCD33 BiKEs
3 more in the full profile.
Beyond the preview
Go deeper on Bispecific Killer Cell Engager (BiKE).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bispecific Killer Cell Engager (BiKE).